147 related articles for article (PubMed ID: 33093335)
1. Epigenetic in medullary thyroid cancer: the role of microRNA in tumorigenesis and prognosis.
Manso J; Censi S; Mian C
Curr Opin Oncol; 2021 Jan; 33(1):9-15. PubMed ID: 33093335
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives.
Galuppini F; Censi S; Moro M; Carraro S; Sbaraglia M; Iacobone M; Fassan M; Mian C; Pennelli G
Cells; 2021 Apr; 10(4):. PubMed ID: 33924120
[TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.
Chu YH; Lloyd RV
Endocr Pathol; 2016 Dec; 27(4):312-324. PubMed ID: 27539727
[TBL] [Abstract][Full Text] [Related]
4. Two GEO MicroRNA Expression Profile Based High-Throughput Screen to Identify MicroRNA-31-3p Regulating Growth of Medullary Thyroid Carcinoma Cell by Targeting RASA2.
Jiang M; Shi X; Zhu H; Wei W; Li J
Med Sci Monit; 2019 Jul; 25():5170-5180. PubMed ID: 31298226
[TBL] [Abstract][Full Text] [Related]
5. miR‑592 acts as an oncogene and promotes medullary thyroid cancer tumorigenesis by targeting cyclin‑dependent kinase 8.
Liu T; Meng J; Zhang Y
Mol Med Rep; 2020 Oct; 22(4):3316-3326. PubMed ID: 32945439
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of RET receptor tyrosine kinase and non-coding RNAs in MTC.
Joo LJS; Zhao JT; Gild ML; Glover AR; Sidhu SB
Mol Cell Endocrinol; 2018 Jul; 469():48-53. PubMed ID: 28315378
[TBL] [Abstract][Full Text] [Related]
7. Analytical and clinical validation of pairwise microRNA expression analysis to identify medullary thyroid cancer in thyroid fine-needle aspiration samples.
Ciarletto AM; Narick C; Malchoff CD; Massoll NA; Labourier E; Haugh K; Mireskandari A; Finkelstein SD; Kumar G
Cancer Cytopathol; 2021 Mar; 129(3):239-249. PubMed ID: 33017868
[TBL] [Abstract][Full Text] [Related]
8. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
Barletta JA; Nosé V; Sadow PM
Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.
Lassalle S; Zangari J; Popa A; Ilie M; Hofman V; Long E; Patey M; Tissier F; Belléannée G; Trouette H; Catargi B; Peyrottes I; Sadoul JL; Bordone O; Bonnetaud C; Butori C; Bozec A; Guevara N; Santini J; Hénaoui IS; Lemaire G; Blanck O; Vielh P; Barbry P; Mari B; Brest P; Hofman P
Oncotarget; 2016 May; 7(21):30461-78. PubMed ID: 27036030
[TBL] [Abstract][Full Text] [Related]
10. Detection of Molecular Alterations in Taiwanese Patients with Medullary Thyroid Cancer Using Whole-Exome Sequencing.
Chang YS; Chang CC; Huang HY; Lin CY; Yeh KT; Chang JG
Endocr Pathol; 2018 Dec; 29(4):324-331. PubMed ID: 30120715
[TBL] [Abstract][Full Text] [Related]
11. Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.
Romeo P; Colombo C; Granata R; Calareso G; Gualeni AV; Dugo M; De Cecco L; Rizzetti MG; Zanframundo A; Aiello A; Carcangiu ML; Gloghini A; Ferrero S; Licitra L; Greco A; Fugazzola L; Locati LD; Borrello MG
Endocr Relat Cancer; 2018 Mar; 25(3):217-231. PubMed ID: 29298817
[TBL] [Abstract][Full Text] [Related]
12. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome.
Mian C; Pennelli G; Fassan M; Balistreri M; Barollo S; Cavedon E; Galuppini F; Pizzi M; Vianello F; Pelizzo MR; Girelli ME; Rugge M; Opocher G
Thyroid; 2012 Sep; 22(9):890-6. PubMed ID: 22747440
[TBL] [Abstract][Full Text] [Related]
15. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K; Simeakis G; Karapanou O; Alevizaki M
Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
[TBL] [Abstract][Full Text] [Related]
16. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
[TBL] [Abstract][Full Text] [Related]
17. Expression of MicroRNAs in Thyroid Carcinoma.
Zhu G; Xie L; Miller D
Methods Mol Biol; 2017; 1617():261-280. PubMed ID: 28540691
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of miRNAs expression in medullary thyroid carcinoma tissue samples: miR-34a and miR-144 as promising overexpressed markers in MTC.
Shabani N; Razaviyan J; Paryan M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
Hum Pathol; 2018 Sep; 79():212-221. PubMed ID: 29885402
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
20. Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.
El Naofal M; Kim A; Yon HY; Baity M; Ming Z; Bui-Griffith J; Tang Z; Robinson M; Grubbs EG; Cote GJ; Hu P
Ann Clin Lab Sci; 2017 Sep; 47(5):523-528. PubMed ID: 29066476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]